Kevin M Alexander
Kevin M Alexander, MD, FACC is an expert in Cardiology at Stanford University School of Medicine (United States). As of October 2026, ScienceLeadR ranks Kevin M Alexander in the top 1% of experts worldwide for Proteostasis Deficiencies and Cardiomyopathies. Kevin M Alexander has authored 116 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 2 of them ongoing. SLR score: 589 (community average: 125). How the SLR is computed.
LeadR Profile
Cardiology
Subspecialties: Biochemistry - Hematology - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026
Number : 116
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Implications of Serum Transthyretin to NT-proBNP Ratio in Transthyretin Amyloid Cardiomyopathy: Insights From ATTRibute-CM. PMID 42862130 — serum, heart failure, prealbumin, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy | JACC Heart Fail | 2026 | 0 |
| Atrial fibrillation in transthyretin amyloid cardiomyopathy: marker of disease severity and implications for multidomain reassessment. PMID 42734712 — muscular diseases, mortality, heart failure, prealbumin, atrial fibrillation, therapeutics, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy | Heart Fail Rev | 2026 | 0 |
| Susceptibility and screening approaches in systemic amyloidosis: expert perspectives from the International Society of Amyloidosis (ISA). PMID 42695486 — early diagnosis, biomarkers, amyloidosis, diagnosis, artificial intelligence | Amyloid | 2026 | 1 |
| 124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial. PMID 42669054 — tomography, positron-emission tomography, predictive value of tests, positron emission tomography computed tomography, amyloidosis, physicians, diagnosis, amyloid, non-randomized controlled trials as topic, sensitivity and specificity | JAMA Top journal | 2026 | 0 |
| Long-term effects of acoramidis on mortality in variant transthyretin amyloid cardiomyopathy, including p.Val142Ile: findings from the open-label extension of ATTRibute-CM. PMID 42669031 — mortality, heart failure, prealbumin, amyloid, cardiomyopathies, transthyretin amyloid cardiomyopathy | Eur J Heart Fail | 2026 | 0 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| OverTTuRe Characteristics Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis NCT06355934 — quality of life, activities of daily living, multiple chronic conditions, amyloidosis, therapeutics, data analysis, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis | N/A | Recruiting | 2023 |
| Open Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants NCT04988386 — amyloid neuropathies, safety, prealbumin, amyloid, cardiomyopathies, amyloid neuropathies, familial, transthyretin amyloid cardiomyopathy, transthyretin amyloidosis | Phase 3 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map